Understanding Parkinson’s Disease: Science, Heart Health, and Living with the Diagnosis

by Usha Nagavarapu, Phd, AD

When my father was diagnosed in 2014, I already knew the word tremor. But as a neuroscience and pharmacology PhD, I also knew the disease inside and out: the loss of dopaminergic neurons, the mechanisms of levodopa, and the long list of non-motor symptoms.

Yet, understanding a condition as a scientist is very different from watching someone you love live with it. Parkinson’s is often described simply as a movement disorder, but that label only scratches the surface. What the textbooks cannot convey is how it feels when it is your own father.

What Is Parkinson's Disease?

Parkinson's is a progressive neurological condition. It develops when nerve cells in the substantia nigra, a region of the brain responsible for movement control, gradually lose their ability to produce dopamine. As dopamine levels decline, the brain's signals for smooth, coordinated movement become disrupted. Its underlying causes remain incompletely understood, and the condition unfolds differently in every individual.

The Motor Symptoms

These are the primary motor features most commonly recognized:

• Tremor: Often starting in one hand while at rest, as it did for my father.

• Slowness of movement (Bradykinesia): Everyday tasks take longer, steps become shorter, and movements lose their natural ease.

• Rigidity: Stiffness in the limbs or trunk that causes discomfort and fatigue.

• Postural instability: Balance changes, particularly in later stages, which increase the risk of falls.

• Speech and handwriting changes: Voices may soften or become monotone, and handwriting often grows noticeably smaller (micrographia).

The Invisible Symptoms

Parkinson's extends far beyond movement. Many individuals face non-motor symptoms that can be just as challenging as motor difficulties:

• Fatigue and disrupted sleep patterns

• Constipation and autonomic digestive changes

• Low mood, anxiety, or apathy

• Impaired sense of smell (anosmia)

• Dizziness upon standing (orthostatic hypotension), caused by blood pressure drops

• Difficulty swallowing (dysphagia) in advanced stages

• Cognitive changes affecting memory and executive function

Because these symptoms are easy to misattribute to normal aging, identifying them explicitly is critical, many can be managed or eased with targeted medical support.

The Gut-Brain Axis and Early Non-Motor Changes

Emerging research reveals that Parkinson's pathology may actually originate in the enteric nervous system, the vast neural network woven throughout our gastrointestinal tract, often referred to as the "second brain." According to the dual-hit hypothesis, pathological misfolded alpha-synuclein proteins may first form in the gut before migrating via the vagus nerve to the brainstem and substantia nigra.

This pathway helps explain why chronic constipation and digestive changes often precede motor symptoms by years or even decades. Recognizing the gut-brain connection highlights the critical role of digestive health: maintaining gut microbiome diversity through hydration, fiber, and gentle motility support is not merely about abdominal comfort, it directly influences overall metabolic resilience and drug absorption. (Chen M etal., 2023)

Medication: Benefits and Trade-offs

Medications, most commonly levodopa combined with a dopa-decarboxylase inhibitor like carbidopa or benserazide, replenish or support dopamine pathways. While highly effective, they come with trade-offs. Side effects include nausea, lightheadedness, drowsiness, and involuntary movements (dyskinesias). Over time, the therapeutic window narrows, leading to motor fluctuations ("wearing-off" periods). In my father's case, the medications sometimes drained his energy more than the disease itself.

A Critical Nuance: Timing Levodopa with Dietary Protein

One crucial factor often overlooked in daily care is the interaction between levodopa and dietary protein. Dietary amino acids share the same active transport channels across the intestinal wall and blood-brain barrier as levodopa. When consumed alongside protein-rich foods, levodopa must compete for absorption, which can delay or reduce its therapeutic effect.

• Best Practice: Take levodopa at least 30 to 60 minutes before meals (or two hours after). If protein interference remains an issue, shifting the majority of daily protein intake to the evening meal can help maintain consistent medication response during active daytime hours. (Cereda et al., 2021)

Cardiovascular Effects and Blood Pressure

Levodopa also exerts prominent systemic effects on the cardiovascular system, which is particularly relevant for older adults with underlying heart conditions.

In a clinical physiological study of 17 patients with moderate Parkinson's disease, a single dose of levodopa/benserazide (200/50 mg) produced a 15% reduction in mean arterial pressure (MAP), while heart rate and systemic vascular resistance remained unchanged. The researchers concluded that this acute drop in blood pressure stems primarily from a negative inotropic effect, reducing the force of cardiac contraction, rather than peripheral vasodilation (Noack et al., 2014).

Recent pharmacodynamic evaluation further demonstrates this acute hypotensive effect. In a study examining oral carbidopa/levodopa administration, seated mean arterial pressure dropped significantly from a baseline average of 105 mmHg to a minimum of 84 mmHg, with the peak decline occurring 100 minutes post-dose. Furthermore, higher cumulative levodopa exposure directly correlated with lower blood pressure ($r = -0.30, p = 0.00036$) (Longardner et al., 2025).

While dopamine inherently increases cardiac contractile force and vascular tone, carbidopa is co-administered to block this conversion outside the central nervous system. Nevertheless, levodopa therapy can still induce significant systemic blood pressure drops. Case literature highlights that initiating levodopa in patients with severe, pre-existing coronary artery disease requires careful cardiovascular monitoring to mitigate ischemia risks (Ng et al., 2019).

Together, the evidence indicates that levodopa can cause short-term hypotension and acute reductions in cardiac output, posing elevated risks for older adults with pre-existing heart disease or baseline low blood pressure.

Navigating Treatment over Time

While levodopa provides essential relief, its benefits can become less predictable over time. If a loved one's treatment appears only partially effective or causes sudden fluctuations, it is vital to speak with their neurologist. Medication adjustments, adjunctive therapies, and supportive care can significantly improve stability.

As Parkinson's progresses, co-occurring conditions, such as cardiovascular disease, diabetes, urinary dysfunction, and joint stiffness, often require parallel management. When multiple medications are prescribed, ask the care team for regular comprehensive medication reviews involving both the neurologist and a cardiologist.

Practical Appointment Checklist for Caregivers

• Maintain a Symptom & Medication Log: Track "ON" periods (when medication effectively manages symptoms), "OFF" periods (when stiffness or tremor returns), and dyskinesias.

• Monitor Blood Pressure at Home: Record seated and standing blood pressure readings, especially if lightheadedness or dizziness occurs after dosing.

• Advocate for Interdisciplinary Support: Request referrals early for specialized physical therapy, occupational therapy, and speech-language evaluation.

Every Journey Is Different: Neuroplasticity and Movement Therapies

No two journeys with Parkinson's are identical. Rates of progression, symptom profiles, and treatment responses vary widely. While pharmacological management remains foundational, targeted physical exercise serves as a powerful stimulus for neuroplasticity, the brain’s ability to adapt, reorganize, and protect neural networks.

Incorporating structured movement therapies can dramatically preserve functional independence:

• LSVT BIG Therapy: A specialized physical therapy protocol designed to recalibrate brain perceptions of movement amplitude, training individuals to take wider strides and perform larger arm movements.

• Targeted Motor Programs: Activities such as boxing, stationary cycling, and Dance for PD combine physical exertion with cognitive challenge and rhythm, improving posture, spatial awareness, and gait fluidity.

An Ayurvedic Perspective: Kampavata and Vata Regulation

In traditional Ayurvedic medicine, the clinical presentation of Parkinson’s disease aligns closely with Kampavata, a condition resulting from an aggravation of Vata dosha. In Ayurvedic physiology, Vata represents the biological energy governing movement, circulation, and nervous system impulses. When Vata becomes hyperactive or imbalanced, often associated with dryness, depletion, and structural degeneration, it manifests as tremors (Kampa), muscle rigidity, and movement slowness.

Integrative strategies aim to calm and nourish Vata through grounding, stabilizing practices:

• Botanical Therapeutics: Mucuna pruriens (Kapikacchu) serves as a natural botanical source of L-dopa and has a long history of clinical use in Ayurvedic formulations alongside modern study. Adaptogenic herbs like Ashwagandha help nourish the nervous system and build systemic vitality (Ojas).

• Nourishing Therapies: Nourishing diet and warm herbal oil applications (Abhyanga) and systemic grounding protocols help mitigate neuromuscular stiffness, reduce systemic dryness, and support restful sleep.

Integrative Guidance at Surrasa

I approach Parkinson's care through two distinct perspectives: as a neuroscience and pharmacology researcher, and as an integrative Ayurvedic practitioner. At Surrasa.com, I help individuals and families understand how the brain and body interact, offering supportive Ayurvedic lifestyle guidance.

To learn more or schedule a personal consultation, visit surrasa.com.

Disclaimer: This content is intended for educational purposes and personal reflection only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding medical conditions or medication adjustments.

References

1. Chen M, Mor DE. Gut-to-Brain α-Synuclein Transmission in Parkinson's Disease: Evidence for Prion-like Mechanisms. Int J Mol Sci. 2023 Apr 13;24(8):7205. doi: 10.3390/ijms24087205. PMID: 37108366; PMCID: PMC10139032.
2. Cereda E, Barichella M, Pedrolli C, Pezzoli G. Low-protein and protein-redistribution diets for Parkinson's disease patients with motor fluctuations: a systematic review. Mov Disord. 2010 Oct 15;25(13):2021-34. doi: 10.1002/mds.23226. PMID: 20669318.

3. Jenkins, R. B., Mendelson, S. H., Lamid, S., & Klawans, H. L. (1972). Levodopa therapy of patients with parkinsonism and heart disease. British Medical Journal, 3(5825), 512–514. https://doi.org/10.1136/bmj.3.5825.512

4. Noack, C., Schroeder, C., Heusser, K., & Lipp, A. (2014). Cardiovascular effects of levodopa in Parkinson's disease. Parkinsonism & Related Disorders, 20(8), 815–818. https://doi.org/10.1016/j.parkreldis.2014.04.007

5. Ng, C. F., Tiau, P. W., Tan, H. J., & Norlinah, M. I. (2019). Levodopa-induced myocardial infarction in a patient with Parkinson's disease and severe coronary artery disease. Journal of the Royal College of Physicians of Edinburgh, 49(1), 37–39. https://doi.org/10.4997/JRCPE.2019.108

6. Longardner, K., Liu, C., Momper, J., Mahato, K., Moonla, C., Ghodsi, H., Wang, J., & Litvan, I. (2025). Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease. Pharmacotherapy, 45(11), 721–728. https://doi.org/10.1002/phar.70066

7. U.S. Food and Drug Administration. (n.d.). Carbidopa and levodopa tablets prescribing information. MedLibrary. https://medlibrary.org